WallStSmart

Lineage, Inc. Common Stock (LINE)vsRithm Capital Corp. (RITM)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 10% more annual revenue ($5.36B vs $4.86B). RITM leads profitability with a 10.2% profit margin vs -4.2%. RITM earns a higher WallStSmart Score of 65/100 (C+).

LINE

Avoid

33

out of 100

Grade: F

Growth: 3.3Profit: 3.0Value: 5.0Quality: 3.5
Piotroski: 2/9Altman Z: 0.67

RITM

Buy

65

out of 100

Grade: C+

Growth: 8.7Profit: 6.0Value: 7.7Quality: 2.5
Piotroski: 2/9Altman Z: 0.40
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LINE.

RITMUndervalued (+84.9%)

Margin of Safety

+84.9%

Fair Value

$70.68

Current Price

$8.05

$62.63 discount

UndervaluedFair: $70.68Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

RITM4 strengths · Avg: 9.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
57.6%10/10

Revenue surging 57.6% year-over-year

P/E RatioValuation
14.7x8/10

Attractively priced relative to earnings

Operating MarginProfitability
20.2%8/10

Strong operational efficiency at 20.2%

Areas to Watch

LINE4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
2.1%3/10

Operating margin of 2.1%

Debt/EquityHealth
1.143/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

RITM4 concerns · Avg: 2.0/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Free Cash FlowQuality
$-1.77B2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

Debt/EquityHealth
4.901/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : RITM

The strongest argument for RITM centers on Price/Book, Revenue Growth, P/E Ratio. Revenue growth of 57.6% demonstrates continued momentum.

Bear Case : LINE

The primary concerns for LINE are EPS Growth, Operating Margin, Debt/Equity.

Bear Case : RITM

The primary concerns for RITM are Piotroski F-Score, Free Cash Flow, Altman Z-Score. Debt-to-equity of 4.90 is elevated, increasing financial risk.

Key Dynamics to Monitor

LINE profiles as a turnaround stock while RITM is a growth play — different risk/reward profiles.

RITM carries more volatility with a beta of 1.16 — expect wider price swings.

RITM is growing revenue faster at 57.6% — sustainability is the question.

LINE generates stronger free cash flow (-183M), providing more financial flexibility.

Bottom Line

RITM scores higher overall (65/100 vs 33/100) and 57.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.

Visit Website →

Rithm Capital Corp.

REAL ESTATE · REIT - MORTGAGE · USA

Rhythm Capital Corp. The company is headquartered in New York, New York.

Want to dig deeper into these stocks?